Aim immunotech announces two year extension of agreement with shenzhen smoore technology limited to develop and test a new inhalation delivery device for ampligen

Announces plans to conduct phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive announces plans to conduct phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive
AIM Ratings Summary
AIM Quant Ranking